Corporate profile
Enlivex is a clinical stage biopharmaceutical company developing Allocetra™, a universal, off-the-shelf cell therapy platform designed to restore the homeostatic state of macrophages, for the treatment of inflammatory diseases.
Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening and life-debilitating conditions.
Investment Highlights
Strong IP strategy for novel therapeutic modality.
Favorable safety profile demonstrated across several clinical studies.
Proposed MOA supported by clinical data.
Optimized manufacturing process yielding ready-to-use doses of off-the-shelf cell therapy platform.
Multi-billion-dollar market opportunity in several inflammatory disease markets with high unmet need.
Seasoned management team with a track record of successfully advancing therapies through regulatory approval.
May
2025
April
2025
April
2025
